Association between CTLA-4 rs231775 polymorphism and risk of colorectal cancer: A meta analysis

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 1, 2015, Pages 650-657

  Wang, Lijie ^a   Jing, Fangfang ^a   Su, Dan ^a   Zhang, Tingting ^a   Yang, Bo ^a   Jiao, Shunchang ^a   Hu, Yi ^a   Bai, Li ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

CRC; CTLA 4; Polymorphism; Risk; Rs231775

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CAUCASIAN; COLORECTAL CANCER; DATA EXTRACTION; DNA POLYMORPHISM; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MEDICAL LITERATURE; META ANALYSIS; PUBLICATION; QUANTITATIVE ANALYSIS;

EID: 84922962865     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Ward E, Jemal A, Cokkinides V, Singh GK, Cardinez C, Ghafoor A and Thun M. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 2004; 54: 78-93.
3. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A and Hemminki K. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85.
4. Johns LE and Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001; 96: 2992-3003.
5. Baglietto L, Jenkins MA, Severi G, Giles GG, Bishop DT, Boyle P and Hopper JL. Measures of familial aggregation depend on definition of family history: meta-analysis for colorectal cancer. J Clin Epidemiol 2006; 59: 114-124.
6. Grady WM. Genetic testing for high-risk colon cancer patients. Gastroenterology 2003; 124: 1574-1594.
7. Peggs KS, Quezada SA, Korman AJ and Allison JP. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006; 18: 206-213.
8. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC and Puccetti P. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097-1101.
9. Manzotti CN, Tipping H, Perry LC, Mead KI, Blair PJ, Zheng Y and Sansom DM. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells. Eur J Immunol 2002; 32: 2888-2896.
10. Schneider H, Valk E, Leung R and Rudd CE. CTLA-4 activation of phosphatidylinositol 3-kinase (PI 3-K) and protein kinase B (PKB/AKT) sustains T-cell anergy without cell death. PLoS One 2008; 3: e3842.
11. Tivol EA, Schweitzer AN and Sharpe AH. Costimulation and autoimmunity. Curr Opin Immunol 1996; 8: 822-830.
12. Thompson CB and Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997; 7: 445-450.
13. Contardi E, Palmisano GL, Tazzari PL, Martelli AM, Fala F, Fabbi M, Kato T, Lucarelli E, Donati D, Polito L, Bolognesi A, Ricci F, Salvi S, Gargaglione V, Mantero S, Alberghini M, Ferrara GB and Pistillo MP. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 2005; 117: 538-550.
14. Su TH, Chang TY, Lee YJ, Chen CK, Liu HF, Chu CC, Lin M, Wang PT, Huang WC, Chen TC and Yang YC. CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis 2007; 28: 1237-1240.
15. Sun T, Hu Z, Shen H and Lin D. Genetic polymorphisms in cytotoxic T-lymphocyte antigen 4 and cancer: the dialectical nature of subtle human immune dysregulation. Cancer Res 2009; 69: 6011-6014.
16. Bouqbis L, Izaabel H, Akhayat O, Perez-Lezaun A, Calafell F, Bertranpetit J and Comas D. Association of the CTLA4 promoter region (-1661G allele) with type 1 diabetes in the South Moroccan population. Genes Immun 2003; 4: 132-137.
17. Vaidya B, Imrie H, Perros P, Young ET, Kelly WF, Carr D, Large DM, Toft AD, McCarthy MI, Kendall-Taylor P and Pearce SH. The cytotoxic T lymphocyte antigen-4 is a major Graves’ disease locus. Hum Mol Genet 1999; 8: 1195-1199.
18. Solerio E, Tappero G, Iannace L, Matullo G, Ayoubi M, Parziale A, Cicilano M, Sansoe G, Framarin L, Vineis P and Rosina F. CTLA4 gene polymorphism in Italian patients with colorectal adenoma and cancer. Dig Liver Dis 2005; 37: 170-175.
19. Cozar JM, Romero JM, Aptsiauri N, Vazquez F, Vilchez JR, Tallada M, Garrido F and Ruiz-Cabello F. High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer. Hum Immunol 2007; 68: 698-704.
20. Hadinia A, Hossieni SV, Erfani N, Saberi-Firozi M, Fattahi MJ and Ghaderi A. CTLA-4 gene promoter and exon 1 polymorphisms in Iranian patients with gastric and colorectal cancers. J Gastroenterol Hepatol 2007; 22: 2283-2287.
21. Dilmec F, Ozgonul A, Uzunkoy A and Akkafa F. Investigation of CTLA-4 and CD28 gene polymorphisms in a group of Turkish patients with colorectal cancer. Int J Immunogenet 2008; 35: 317-321.
22. Qi P, Ruan CP, Wang H, Zhou FG, Xu XY, Gu X, Zhao YP, Dou TH and Gao CF. CTLA-4 +49A>G polymorphism is associated with the risk but not with the progression of colorectal cancer in Chinese. Int J Colorectal Dis 2010; 25: 39-45.
23. Li XD, Zhao JP and Sun YY. Relationship between cytotoxic T lymphocyte associated with antigen-4 +49A > G gene polymorphism and colorectal cancer in Chinese. Chin J Biologicals 2011; 24: 1038-1041.
24. Fan ZG, FJ, CT and GJ W. Association between cytotoxic T-lymphocyte antigen-4 +49 A > G gene polymorphism and colorectal cancer. Hei Long Jiang Medical Journal 2012; 36: 810-811.
25. Cui JY, MH, Cui WL, Ma WH and Qi YQ. Association of cytotoxic T-lymphocyte gene polymorphism and with susceptibility on colorectal cancer. J Pharmacol Exp Ther 2013; 16: 127-130.
26. Zheng J, Yu X, Jiang L, Xiao M, Bai B, Lu J and Zhou Y. Association between the Cytotoxic T-lymphocyte antigen 4 +49G > A polymorphism and cancer risk: a meta-analysis. BMC Cancer 2010; 10: 522.
27. Zhang Y, Zhang J, Deng Y, Tian C, Li X, Huang J and Fan H. Polymorphisms in the cytotoxic T-lymphocyte antigen 4 gene and cancer risk: a meta-analysis. Cancer 2011; 117: 4312-4324.
28. Geng R, Song F, Yang X, Sun P, Hu J, Zhu C, Zhu B and Fan W. Association between cytotoxic T lymphocyte antigen-4 +49A/G,-1722T/C, and-1661A/G polymorphisms and cancer risk: a meta-analysis. Tumour Biol 2014; 35: 3627-3639.
29. Mantel N and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
30. DerSimonian R and Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
31. Egger M, Davey Smith G, Schneider M and Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
32. Ferrari P, Jenab M, Norat T, Moskal A, Slimani N, Olsen A, Tjonneland A, Overvad K, Jensen MK, Boutron-Ruault MC, Clavel-Chapelon F, Morois S, Rohrmann S, Linseisen J, Boeing H, Bergmann M, Kontopoulou D, Trichopoulou A, Kassapa C, Masala G, Krogh V, Vineis P, Panico S, Tumino R, van Gils CH, Peeters P, Bueno-de-Mesquita HB, Ocke MC, Skeie G, Lund E, Agudo A, Ardanaz E, Lopez DC, Sanchez MJ, Quiros JR, Amiano P, Berglund G, Manjer J, Palmqvist R, Van Guelpen B, Allen N, Key T, Bingham S, Mazuir M, Boffetta P, Kaaks R and Riboli E. Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 2007; 121: 2065-2072.
33. Li S, Nie Z, Li N, Li J, Zhang P, Yang Z, Mu S, Du Y, Hu J, Yuan S, Qu H, Zhang T, Wang S, Dong E and Qi D. Colorectal cancer screening for the natural population of Beijing with sequential fecal occult blood test: a multicenter study. Chin Med J (Engl) 2003; 116: 200-202.
34. Mapara MY and Sykes M. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004; 22: 1136-1151.
35. Ligers A, Teleshova N, Masterman T, Huang WX and Hillert J. CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2001; 2: 145-152.